<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01230970</url>
  </required_header>
  <id_info>
    <org_study_id>X-55-58064-005</org_study_id>
    <nct_id>NCT01230970</nct_id>
  </id_info>
  <brief_title>Exploratory Study to Assess the Short Term Intratumoural and Peripheral Effects of BN83495 in Postmenopausal Women With Newly Diagnosed Breast Cancer</brief_title>
  <official_title>A Phase II, Open-label, Exploratory Study to Assess the Short Term Intratumoural and Peripheral Effects of BN83495 Administered for 14 Days Prior to Surgery to Postmenopausal Women With Newly Diagnosed Primary Invasive Oestrogen Receptor Positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ipsen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will assess the intratumoural pharmacological activity of BN83495 by changes in
      intratumoural levels of sex hormones and associated inhibition of steroid sulphatase (STS)
      activity.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The futility analysis of study NCT00910091 in patients with endometrial cancer shows that the
    primary endpoint will not be reached.
  </why_stopped>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intratumoural levels of sex hormones</measure>
    <time_frame>Baseline and Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Intratumoural steroid sulphatase activity</measure>
    <time_frame>Baseline and Day 14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the intratumoural Ki67 proliferation index</measure>
    <time_frame>Baseline and Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with a decrease in Ki67 staining ≥50%</measure>
    <time_frame>Baseline and Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with complete cell cycle response, defined as Ki67 staining ≤1%</measure>
    <time_frame>Baseline and Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Apoptotic Index determined by M30 antibody</measure>
    <time_frame>Baseline and Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Growth Index (Ki67 proliferation index/M30 apoptotic index)</measure>
    <time_frame>Baseline and Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in steroid sulphatase activity in peripheral blood mononuclear cells (PBMCs).</measure>
    <time_frame>Baseline and Day 14</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>BN83495</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40mg tablet oral daily administration from Day 1 to Day 14.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BN83495</intervention_name>
    <description>40mg tablet oral daily administration from Day 1 to Day 14.</description>
    <arm_group_label>BN83495</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female subjects 55 to 80 years with histologically or cytologically documented primary
             intraductal or lobular invasive breast cancer that meets the following criteria:

          -  T2, N0 or N1, M0.

          -  Primary tumour clinically determined to be 2 to 5 cm in the greatest dimension.

          -  Laboratory documentation of positive oestrogen receptor (ER+) status in at least 10%
             of the tumour cells.

          -  Laboratory documentation of HER-2 negative status.

        Postmenopausal defined as

          -  no spontaneous menses for a total of 2 years

          -  amenorrheic for at least 12 months with serum oestrogen level &lt;30 pg/mL, and both
             luteinising hormone (LH)/follicle stimulating hormone (FSH) &gt;20 IU/L,
             chemotherapy-induced amenorrhoea for at least 12 months

          -  bilateral oophorectomy, or radiation castration and amenorrhoeic for at least 3
             months.

        Eastern Cooperative Oncology Group (ECOG) performance status ≤2.

        Exclusion Criteria:

          -  Has locally advanced breast cancer that is considered non-operable without neoadjuvant
             therapy.

          -  Has evidence of metastatic disease

          -  as a diagnosis of inflammatory breast cancer

          -  Has ductal carcinoma in situ
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Kornowski, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ipsen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Akershus University Hospital</name>
      <address>
        <city>Lørenskog</city>
        <zip>1474</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2010</study_first_submitted>
  <study_first_submitted_qc>October 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2010</study_first_posted>
  <last_update_submitted>October 10, 2013</last_update_submitted>
  <last_update_submitted_qc>October 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

